Dong-A Socio Holdings Co., Ltd. (000640.KS)
KRW 110000.0
(4.86%)
KRW 110000.0
(4.86%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 364.1 Billion KRW | 23.64% |
| 2022 | 294.38 Billion KRW | 4.58% |
| 2021 | 281.48 Billion KRW | 7.44% |
| 2020 | 261.98 Billion KRW | -1.12% |
| 2019 | 264.95 Billion KRW | 12.57% |
| 2018 | 235.36 Billion KRW | -4.23% |
| 2017 | 245.76 Billion KRW | -13.25% |
| 2016 | 283.31 Billion KRW | 14.51% |
| 2015 | 247.41 Billion KRW | 29.17% |
| 2014 | 191.53 Billion KRW | 4.07% |
| 2013 | 184.04 Billion KRW | -63.06% |
| 2012 | 498.18 Billion KRW | -4.65% |
| 2011 | 522.5 Billion KRW | -0.65% |
| 2010 | 525.92 Billion KRW | 10.09% |
| 2009 | 477.73 Billion KRW | 9.65% |
| 2008 | 435.68 Billion KRW | 14.66% |
| 2007 | 379.97 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 78.58 Billion KRW | 22.42% |
| 2024 Q1 | 88.34 Billion KRW | 37.01% |
| 2023 Q2 | 96.94 Billion KRW | 21.32% |
| 2023 Q1 | 79.91 Billion KRW | 18.03% |
| 2023 Q4 | 64.48 Billion KRW | -36.69% |
| 2023 FY | 363.97 Billion KRW | 23.64% |
| 2023 Q3 | 101.84 Billion KRW | 5.05% |
| 2022 Q1 | 61.28 Billion KRW | -14.5% |
| 2022 Q2 | 82.02 Billion KRW | 33.83% |
| 2022 Q3 | 83.36 Billion KRW | 1.64% |
| 2022 Q4 | 67.7 Billion KRW | -18.79% |
| 2022 FY | 294.38 Billion KRW | 4.58% |
| 2021 Q1 | 56.96 Billion KRW | -5.94% |
| 2021 Q2 | 75.53 Billion KRW | 32.59% |
| 2021 Q3 | 77.29 Billion KRW | 2.33% |
| 2021 Q4 | 71.68 Billion KRW | -7.27% |
| 2021 FY | 281.48 Billion KRW | 7.44% |
| 2020 Q2 | 68.73 Billion KRW | 21.71% |
| 2020 FY | 261.98 Billion KRW | -1.12% |
| 2020 Q1 | 56.47 Billion KRW | -12.19% |
| 2020 Q4 | 60.56 Billion KRW | -20.54% |
| 2020 Q3 | 76.21 Billion KRW | 10.89% |
| 2019 Q1 | 52.08 Billion KRW | -12.23% |
| 2019 FY | 264.95 Billion KRW | 12.57% |
| 2019 Q4 | 64.3 Billion KRW | -14.04% |
| 2019 Q3 | 74.81 Billion KRW | 1.46% |
| 2019 Q2 | 73.73 Billion KRW | 41.57% |
| 2018 Q2 | 67.01 Billion KRW | 30.6% |
| 2018 Q1 | 51.3 Billion KRW | -10.85% |
| 2018 FY | 235.36 Billion KRW | -4.23% |
| 2018 Q4 | 59.34 Billion KRW | 2.88% |
| 2018 Q3 | 57.69 Billion KRW | -13.91% |
| 2017 FY | 245.76 Billion KRW | -13.25% |
| 2017 Q4 | 57.55 Billion KRW | -15.04% |
| 2017 Q3 | 67.74 Billion KRW | -1.33% |
| 2017 Q2 | 68.65 Billion KRW | 32.49% |
| 2017 Q1 | 51.81 Billion KRW | -30.81% |
| 2016 Q2 | 92.27 Billion KRW | 60.2% |
| 2016 FY | 283.31 Billion KRW | 14.51% |
| 2016 Q4 | 74.89 Billion KRW | 27.92% |
| 2016 Q1 | 57.6 Billion KRW | -7.8% |
| 2016 Q3 | 58.54 Billion KRW | -36.56% |
| 2015 Q2 | 64.6 Billion KRW | 44.17% |
| 2015 FY | 247.41 Billion KRW | 29.17% |
| 2015 Q1 | 44.81 Billion KRW | -5.4% |
| 2015 Q4 | 62.47 Billion KRW | -17.28% |
| 2015 Q3 | 75.51 Billion KRW | 16.88% |
| 2014 FY | 191.53 Billion KRW | 4.07% |
| 2014 Q3 | 45.86 Billion KRW | -17.16% |
| 2014 Q2 | 55.36 Billion KRW | 28.98% |
| 2014 Q4 | 47.37 Billion KRW | 3.28% |
| 2014 Q1 | 42.92 Billion KRW | -7.85% |
| 2013 Q4 | 46.58 Billion KRW | -5.37% |
| 2013 FY | 184.04 Billion KRW | -63.06% |
| 2013 Q1 | 37.81 Billion KRW | -89.55% |
| 2013 Q2 | 50.42 Billion KRW | 33.35% |
| 2013 Q3 | 49.22 Billion KRW | -2.37% |
| 2012 FY | 498.18 Billion KRW | -4.65% |
| 2012 Q1 | 111.69 Billion KRW | 0.0% |
| 2012 Q2 | 50.04 Billion KRW | -55.19% |
| 2012 Q3 | 48.83 Billion KRW | -2.43% |
| 2012 Q4 | 361.69 Billion KRW | 640.7% |
| 2011 FY | 522.5 Billion KRW | -0.65% |
| 2011 Q3 | 128.18 Billion KRW | -2.49% |
| 2011 Q1 | 127.96 Billion KRW | 0.0% |
| 2011 Q2 | 131.46 Billion KRW | 2.73% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | 124.24 Billion KRW | -7.95% |
| 2010 FY | 525.92 Billion KRW | 10.09% |
| 2010 Q2 | 134.96 Billion KRW | 13.13% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q1 | 119.3 Billion KRW | 0.0% |
| 2009 Q3 | 124.49 Billion KRW | 2.81% |
| 2009 Q2 | 121.09 Billion KRW | 7.34% |
| 2009 Q1 | 112.81 Billion KRW | 0.0% |
| 2009 FY | 477.73 Billion KRW | 9.65% |
| 2009 Q4 | - KRW | -100.0% |
| 2008 FY | 435.68 Billion KRW | 14.66% |
| 2008 Q3 | 116.72 Billion KRW | 4.81% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q1 | 101.71 Billion KRW | 0.0% |
| 2008 Q2 | 111.37 Billion KRW | 9.5% |
| 2007 Q1 | 91.1 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 379.97 Billion KRW | 0.0% |
| 2007 Q2 | 94.86 Billion KRW | 4.14% |
| 2007 Q3 | 102.32 Billion KRW | 7.86% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -682.944% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -83.073% |
| HANDOK Inc. | 151.36 Billion KRW | -140.548% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -441.63% |
| Yuhan Corporation | 564.5 Billion KRW | 35.5% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | -13.003% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -1433.278% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 56.439% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -385.222% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -83.004% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -795.725% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -285.237% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -158.498% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -682.944% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -948.827% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -373.987% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 3122.749% |
| JW Holdings Corporation | 446.15 Billion KRW | 18.39% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | -75.441% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 44.44% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -8.472% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -363.126% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -383.942% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -404.225% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -98.085% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -682.944% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | -23.377% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 46.576% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -8.472% |
| Yuhan Corporation | 564.5 Billion KRW | 35.5% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | -80.411% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -413.269% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -267.686% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | -8.472% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -149.575% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -109.876% |
| CKD Bio Corp. | 5.01 Billion KRW | -7167.2% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | -43.219% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -97.751% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -271.065% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -363.126% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 1.989% |
| Boryung Corporation | 333.26 Billion KRW | -9.254% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -627.555% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -83.004% |
| JW Lifescience Corporation | 51.32 Billion KRW | -609.418% |